reduced-heart-failure-treatment-approval-europe

Jardiance ® (empagliflozin) approved in Europe for the treatment of heart failure with reduced ejection fractionThis new indication is based on the EMPEROR-Reduced trial, which showed a significant 25 percent reduction in the combined relative risk versus placebo of cardiovascular death or hospitalization for heart failure with reduced ejection fraction in adults with or without diabetes and an eGFR of ≥20ml/min/1.73 m2Heart failure is the leading cause of hospitalization in Europe,   with prevalence expected to increase as the population agesJardiance was first approved in May 2014 for the treatment of adults with insufficiently controlled type 2 diabetes mellitus
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news